"Cellceutix anticipates that this type of trial could be completed in an expeditious fashion. The aim is to subsequently enable convenient therapeutic dosing in the ovarian cancer population."

That quote has to do with the pill form of Kevetrin -- the safety trial in healthy volunteers.

So to all the whiners at the other board who are claiming that progress is slow (it isn't) and that Cellceutix management isn't working hard enough (laughable claim) -- your lies and lack of credibility should be obvious now to even the newest of newbie CTIX investors.